Xortx Therapeutics Inc XRTX

$1.71 -0.02 (-0.91%)

Valuation

Market cap
3,143,000
Revenue TTM
$0
Net income TTM
$-2,660,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
4,400
Avg volume
284,740
Day's range
$1.70 – $1.79
Shares out
1,817,000
Stochastic %K
10%
Beta
0.78
Analysts
Strong Buy
Price target
$70.00

Price

Company profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injur...

Show more

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
403 455 7727
Website
https://www.xortx.com
Address
3710 - 33rd Street NW, Calgary, Canada

Latest news